Antiemetic properties of the antiepileptic drug levetiracetam

New England Journal of Medicine

Volumn 359, Issue 17, 2008, Pages 1853-

  Lee, Jong Woo ^a   Bromfield, Edward B ^a   Kesari, Santosh ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETIRACETAM;

ANTIEMETIC ACTIVITY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 54949083842     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0806761     Document Type: Letter

References (4)

1. Lee JW, Bromfield EB, Kesari S. Emesis responsive to levetiracetam. J Neurol Neurosurg Psychiatry 2008;79:847-9.
2. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94.
3. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861-6.
4. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 2008;71:665-9.